Cardio Catch-Up: Trial Of Abbott’s Volt PFA Begins; IDE Study To Start This Year
Executive Summary
Abbott is behind rivals Boston Scientific and Medtronic in the race to capture share of the emerging pulsed field ablation market. PFA is set to eventually become the most common cardiac ablation modality because it is safer than radiofrequency or cryoablation.